Canan Alkim

Canan Alkim

Auto-generated profile, based on publicly available information

Canan Alkim

Sisli Etfal Training and Research Hospital

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2015 in International Journal of Inflammation
Verified
Journal Article
Open access
PDF file
CACanan Alkim
Canan Alkim
HAHuseyin Alkim
Huseyin Alkim
AKAli Riza Koksal
Ali Riza Koksal
SBSalih Boga
Salih Boga
ISIlker Sen
Ilker Sen
Angiogenesis is an important component of pathogenesis of inflammatory bowel disease (IBD). Chronic inflammation and angiogenesis are two closely related processes. Chronic intestinal inflammation is dependent on angiogenesis and this angiogenesis is modulated by immune system in IBD. Angiogenesis is a very complex process which includes multiple cell types, growth factors, cytokines, adhesion molecules, and signal transduction. Lymphangiogenesis is a new research area in the pathogenesis of IBD. While angiogenesis supports inflammation via leukocyte migration, carrying oxygen and nutrients, on the other hand, it has a major role in wound healing. Angiogenic molecules look like perfect targets for the treatment of IBD, but they have risk for serious side effects because of their nature.

1 November 2017 in American Journal of Therapeutics
Verified
Journal Article
Closed access
HAHuseyin Alkim
Huseyin Alkim
AKAli Riza Koksal
Ali Riza Koksal
SBSalih Boga
Salih Boga
ISIlker Sen
Ilker Sen
CACanan Alkim
Canan Alkim
Bismuth salts exert their activity within the upper gastrointestinal tract through action of luminal bismuth. Bismuth exerts direct bactericidal effect on Helicobacter pylori by different ways: forms complexes in the bacterial wall and periplasmic space, inhibits different enzymes, ATP synthesis, and adherence of the bacteria to the gastric mucosa. Bismuth also helps ulcer healing by acting as a barrier to the aggressive factors and increasing mucosal protective factors such as prostaglandin, epidermal growth factor, and bicarbonate secretion. To date, no resistance to bismuth has been reported. Also synergism between bismuth salts and antibiotics was present. It was shown that metronidazole and clarithromycin resistant H. pylori strains become susceptible if they are administered together with bismuth. Bismuth-containing quadruple therapy was recommended both by the Second Asia-Pacific Consensus Guidelines and by the Maastricht IV/Florence Consensus Report as an alternative first choice regimen to standard triple therapy, in areas with low clarithromycin resistance, and it is recommended as the first-line therapeutic option in areas with a high prevalence of clarithromycin resistance. Greater than 90% eradication success can be obtained by bismuth-containing quadruple therapy. Choosing bismuth as an indispensable part of first-line therapy is logical as both metronidazole and clarithromycin resistances can be overcome by adding bismuth to the regimen.

5 July 2004 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
NANi̇hat Akbayir
Ni̇hat Akbayir
CACanan Alkim
Canan Alkim
LELevent Erdem
Levent Erdem
HSH Mehmet Sökmen
H Mehmet Sökmen
ASAyşi̇m Sungun
Ayşi̇m Sungun
ZMZeynel Mungan
Zeynel Mungan

9 November 2004 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
DBDidem Baskın
Didem Baskın
NUNafiye Urgancı
Nafiye Urgancı
LALatif Abbasoğlu
Latif Abbasoğlu
CACanan Alkım
Canan Alkım
MYMehmet Yalçın
Mehmet Yalçın
NSNihat Sever
Nihat Sever

17 May 2011 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
PDF file
HAHuseyin Alkim
Huseyin Alkim
SASelime Ayaz
Selime Ayaz
CACanan Alkim
Canan Alkim
AUAysel Ulker
Aysel Ulker
BSBurhan Sahin
Burhan Sahin
This study was planned for searching possible changes of the total coagulation and fibrinolysis system in inflammatory bowel disease (IBD) in order to obtain some clues for explaining the relation between IBD and hypercoagulability. A total of 24 patients with ulcerative colitis, 12 patients with Crohn disease, and 20 healthy controls were studied. Platelets; prothrombin time (PT); partial thromboplastin time (PTT); fibrinogen; d-dimer; fibrinogen degradation products; protein C; protein S; antithrombin; thrombin time; von Willebrand factor; coagulation factors V, VII, VIII, IX, XI, and XIII; plasminogen; antiplasmin; tissue plasminogen activator; plasminogen activator inhibitor 1; and prothrombin fragments 1 + 2 were studied. Most of the procoagulants (platelets, fibrinogen, von Willebrand factor, coagulation factor IX, and plasminogen activator inhibitor 1) were found increased together with decreases in some anticoagulants (protein S and antithrombin) in IBD. Also the activation markers of coagulation (d-dimer, fibrinogen degradation products, and prothrombin fragments 1 + 2) were all increased. The parameters of the total coagulation–fibrinolysis system were increased in IBD, regardless of the form and the activity of the disease.

18 February 2016 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
HAHuseyin Alkim
Huseyin Alkim
AKAli Riza Koksal
Ali Riza Koksal
SBSalih Boga
Salih Boga
ISIlker Sen
Ilker Sen
CACanan Alkim
Canan Alkim
The close relationship between inflammation and thrombosis affects the progression and severity of inflammatory bowel disease (IBD). The prevalence of venous thromboembolism (VTE) varies between 1% and 7% among patients with IBD. The VTE risk in patients with IBD is at least 3 times higher than that in the normal general population. The absolute risk is very high during hospitalization, active disease, and surgery. The IBD-related VTE occurs at younger ages and recurs more frequently. The development of thrombosis in IBD is due to the interaction of many hereditary and acquired risk factors. Each patient diagnosed with IBD should be evaluated for a personal and family history of thrombosis and for prothrombotic drug use. Although procoagulant factors are increased during the natural course of inflammation, natural anticoagulants and fibrinolytic activity are decreased. Although IBD is accepted as a prothrombotic condition, there is no treatment that can remove this risk from daily practice. Patient training is required to control important factors, such as long-term immobilization and smoking. Oral contraceptives and hormone replacement therapy should be avoided. Inducing permanent disease remission must be the key approach for the prevention of thrombosis. Low-molecular-weight heparin (LMWH) is the basis of prophylactic treatment, which reduces the thrombosis risk by 50%. Prophylaxis with LMWH should be administered to all patients with IBD hospitalized due to disease attack or surgery. Long-term or even life-long anticoagulation therapy should be planned if there is insufficient disease control, recurrent VTE attacks, positive thrombophilia tests, or thrombosis in vital veins.